Fehmi Keçe

Advances in Atrial Fibrillation Ablation Devices 43 2 Table 2. Continued. Author, year (study type) Number of patients, ablation device and protocol* PAF (%) Preventive techniques AAD free survival (1 year) (%) Procedural, ablation time and fluoroscopy time (min) Complications (%) Ciconte, 2015 (84) (observational) N=143; CBA 1x3 79 Phrenic nerve pacing 83 95 N.A. 14 - Transient PNP 6.3; permanent PNP 3.5(recovery <1 year) - Vascular access 1.4 Defaye, 2011 (85) (observational) N=117; CB 2x4 79 Phrenic nerve pacing 69 155 N.A. 35 - Pericardial effusion 1.7 / Cardiac Tamponade 0.9 - Transient ST elevation 0.9 - Transient PNP 3.4 - Other: chest pain/haemoptysis 0.9 Khoueiry, 2016 (86) (observational) N=208 CB; N=103 CBA; CB(A) 2x4 minutes 100 Phrenic nerve pacing 83 133 (p=0.001) N.A. 26 (p=0.005) - Pericarditis/Cardiac tamponade 0.3 - Thromboembolic events 0.3 - Transient phrenic palsy 2.3 (p=0.016) - Gastroparesis 0.3, oesophageal ulcer 0.3 - Vascular complications/major bleeding 2.3 - Other: 0.7 (haemoptysis and hemomediastin) Kuck, 2016(87) (multicenter RCT) N=90 CB; N=279 CBA; CB 1x5; CBA 1x4 100 Phrenic nerve pacing 65 141 (p<0.001) N.A 17 (p<0.001) - Cardiac tamponade/Effusion 0.3 - Stroke/TIA 0.5 and transient neurologic complications 0.3 - Transient an permanent PNP 2.7 (p=0.001) and0.3 - Gastrointestinal complication 0.3 ; oesophageal ulcer 0.3 - Vascular access 1.9 - Other: pulmonary or bronchial complication 0.5; other cardiac complications 0.8, anxiety 0.3 Luik, 2015 (161) (RCT) N=156; CB 2x5; CBA 2x4 100 N.A. 61 161 (IQR 133- 193) (p=0.006) N.A. 25 (IQR 18-31) - Pericardial effusion 1.3 - Transient and permanent PNP 3.8 (p=0.002) and 1.9 - Vascular access 5.1